News & Events

KRAS Mutant NSCLC in 2026: From G12C Inhibition to RAS(ON), Pan-RAS and Combination Strategies

KRAS Mutant NSCLC in 2026: From G12C Inhibition to RAS(ON), Pan-RAS and Combination Strategies

Could Divarasib Challenge Existing KRAS G12C Inhibitors in Lung Cancer?

Could Divarasib Challenge Existing KRAS G12C Inhibitors in Lung Cancer?

Could Divarasib Challenge Existing KRAS G12C Inhibitors in Lung Cancer?

Could Divarasib Challenge Existing KRAS G12C Inhibitors in Lung Cancer?

Frontier Medicines to Present First Clinical Data for FMC-376, an Equipotent KRAS G12C ON+OFF Inhibitor, at ESMO Congress 2026

Frontier Medicines to Present First Clinical Data for FMC-376, an Equipotent KRAS G12C ON+OFF Inhibitor, at ESMO Congress 2026

KRAS G12S Positive Non-Small Cell Lung Cancer Mimicking KRAS G12C Positivity on the AmoyDx PCR Panel: A Case Report

KRAS G12S Positive Non-Small Cell Lung Cancer Mimicking KRAS G12C Positivity on the AmoyDx PCR Panel: A Case Report

VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors

VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors

Verastem's KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC

Verastem's KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC

VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors

VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors

VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors

VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors

Efficacy and safety of immune checkpoint inhibitor plus bevacizumab-based chemotherapy in advanced or recurrent KRAS-mutant non-squamous NSCLC: the SPIRAL-STONE study

Efficacy and safety of immune checkpoint inhibitor plus bevacizumab-based chemotherapy in advanced or recurrent KRAS-mutant non-squamous NSCLC: the SPIRAL-STONE study